Improving Outcomes: When Infection Is More Than Skin Deep
Premiere Date: Thursday, April 18, 2013This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, April 18, 2014
Note: Credit Is No Longer Available
 | Michael S. Niederman, MD, FACP, FCCP, FCCM Chairman, Department of Medicine Winthrop-University Hospital Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook Mineola, NY |
 | Benjamin A. Lipsky, MD, FACP, FIDSA, FRCP (Faculty) Emeritus Professor of Medicine University of Washington Visiting Professor, Infectious Diseases Green Templeton College, University of Oxford Deputy Director, Graduate Entry Course University of Oxford Medical School Oxford, UK |
Co-provided by
The number of patients seeking care for skin and soft tissue infections (SSTIs) has been increasing over recent years. Importantly, during this time, antibiotic-resistant bacteria (i.e., “superbugs”) have become an increasing public health problem, and methicillin-resistant Staphylococcus aureus (MRSA) is a leading pathogen. Current practice for complicated SSTIs (cSSTIs) is to assume that cSSTIs are due to MRSA and treat empirically—until proven otherwise—in addition to standard incision and drainage (I & D) of the lesion. However, evidence suggests that the rates at which I & D is performed and appropriate antibiotic coverage for MRSA is provided have room for improvement and can be optimized above current practice.
This Journal Club activity features expert faculty discussing a recent peer-reviewed article reporting a prospective, multicenter study on cSSTI management in the journal, BMC Infectious Diseases. Using the article as a springboard, clinicians will explore the continually changing epidemiology of MRSA infection, the rationale supporting gold-standard I & D, and available data that support optimal selection of antimicrobial therapy.
Discussion topics include:
- Need for and value of a prospective observational study of skin and soft tissue infections (SSTIs)
- The main types of SSTIs that result in hospitalization, and how they are classified
- Demographic and clinical characteristics of patients with various types of SSTIs
- Patterns of treatment (antibiotic and surgical) clinicians do (and perhaps should) provide for hospitalized patients with SSTI
- The outcomes of SSTIs and what factors most influence them.
- Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [erratum, Clin Infect Dis. 2011;53(3):319]. Clin Infect Dis. 2011;52(3):e18-e55. PMID: 21208910.
Featured Article: Lipsky BA, Moran GJ, Napolitano LM, et al. A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes. BMC Infect Dis. 2012;12:227. PMID: 23009247.
View Full Article
To educate clinicians that having high clinical suspicion for MRSA as the infectious agent in complicated skin and soft tissue infections is judicious practice and that such infections warrant the appropriate use of antimicrobial agents, in addition to standard incision and draining.
At the end of this CE activity, participants should be able to:
- Increase clinical suspicion that an encountered complicated skin and soft tissue infection is highly likely to be infected with methicillin-resistant Staphylococcus aureus.
- Perform incision and drainage on lesions displaying complicated skin and soft tissue infection, in accordance with guidelines.
- Select therapy for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus by assessing (a) the comparative antimicrobial spectrum; and (b) the pharmacokinetic and pharmacodynamic profiles and the efficacy and safety data of available antibiotic options.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Summarize the rationale for performing incision and drainage on lesions displaying complicated skin and soft tissue infection.
- Describe the efficacy and safety information for front-line antibiotics used to treat complicated skin and soft tissue infection lesions caused by methicillin-resistant Staphylococcus aureus.
This activity is supported by an educational grant from Pfizer Inc.
Physicians, physician assistants, nurses, nurse practitioners, pharmacists, and other health care professionals who evaluate individuals for skin infections.
CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
USF Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Activity Number: 0376-0000-13-005-L01-P (live programs)
0376-0000-13-005-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST767 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure of Relevant Financial Relationships with Commercial Interests
USF Health and CME Outfitters, LLC, adhere to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of USF Health and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
USF Health will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Niederman has disclosed that he receives research grant/research support from Bayer Corporation and Cubist Pharmaceuticals. He is on the advisory boards of and serves as a consultant to Cubist Pharmaceuticals; Merck & Co Inc.; and Pfizer Inc.
Dr. Lipsky has disclosed that he serves on the advisory board of Cerexa, Inc. He serves as a consultant for Innocoll and Pfizer Inc. He is on the speakers bureaus of Merck & Co Inc. and Novartis Pharmaceuticals.
Disclosures were obtained from the planning committee members and are on file in the USF Health, Office of Continuing Professional Development (OCPD) for review. Disclosures were obtained from the USF Health OCPD staff: Nothing to Disclose.
Nancy Jennings, MSN, MBA, MHA, RNC (content/peer reviewer) has no disclosures to report.
Monique Johnson, MD CCMEP (planning committee) has no disclosures to report.
Joy B. Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
USF Health, CME Outfitters, LLC, the faculty, and Pfizer Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Equal Opportunity Statement: Events, activities, programs and facilities of the University of South Florida are available to all without regard to race, color, marital status, gender, sexual orientation, religion, national origin, disability, age, Vietnam or disabled veteran status as provided by law and in accordance with the university's respect for personal dignity.
Contact Information: If you have technical queries about using this site, please contact webmaster@cmeoutfitters.com.If you have credit related queries, please contact cpdsupport@health.usf.edu
Privacy & Information Required: USF Health Office of Continuing Professional Development (OCPD) has created a privacy policy to demonstrate our commitment to guarding the privacy of our clients. The following statements disclose our practices on gathering and disseminating information for this web site.
The OCPD has security measures in place to protect the loss, misuse, and alteration of the information under our control. The OCPD does not share or sell any individual’s contact information, financial information, or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.
If you have any questions about this privacy policy, please contact USF Health OCPD at cpdsupport@health.usf.edu.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
JC-016-041813-02
